natgillin/translations-raw huggingface dataset:
Get medical help immediately if you have a generalised allergic reaction (hives, trouble breathing, faintness or collapse and feeling generally unwell). if you have finished growing (the bone growth plates are closed).
Potražite odmah medicinsku pomoć kao imate generaliziranu alergijsku reakciju (koprivnjaču, otežano disanje, nesvjesticu ili kolaps i ako se općenito ne osjećate dobro), ako ste prestali rasti (ploče rasta kostiju su zatvorene).
Get medical help immediately, if you get the following symptoms:
Odmah potražite liječničku pomoć ako razvijete sljedeće simptome:
Get medical help immediately, if you get the following symptoms: passing blood in the stools or passing black stools, passing blood in the urine, stomach pain, coughing / vomiting up blood
Odmah potražite liječničku pomoć ako razvijete sljedeće simptome: pojavu krvi u stolici ili crnu boju stolice, pojavu krvi u mokraći, bol u trbuhu, kašalj/povraćanje krvi.
Get medical help immediately, if you get the following symptoms: severe stomach pain or stomach pain that does not go away, vomiting blood, red or black stools
Potražite odmah liječničku pomoć ako razvijete sljedeće simptome: jaku bol u želucu ili bol u želucu koja ne prolazi, povraćanje krvi, crvene ili crne stolice.
Get medical help straight away.
Odmah zatražite medicinsku pomoć.
GET READY
PRIPREMITE SE
get slow or shallow breathing get cold clammy skin, look pale, have a weak pulse or other signs of shock.
počnete disati usporeno ili plitko koža Vam je postala hladna i ljepljiva, blijedi ste, imate slabi puls ili neke druge znakove šoka.
Get tested for other sexually transmitted infections such as syphilis and gonorrhoea.
Testirajte se na druge spolno prenosive bolesti kao što su sifilis i gonoreja.
Get the AZOPT bottle and a mirror
Uzmite bočicu AZOPTA i ogledalo
Get the bottle and a mirror.
Uzmite bočicu i ogledalo.
Get the DuoTrav bottle and a mirror.
Uzmite bočicu DuoTrav kapi i ogledalo.
Get the EMADINE bottle and a mirror.
Pripremite bočicu EMADINE i zrcalo.
Get the OPATANOL bottle and a mirror.
Uzmite bočicu lijeka OPATANOL i ogledalo.
Get to know the ClickJect Pre-filled Pen
Upoznajte svoju napunjenu brizgalicu ClickJect
Get together everything you need and lay them out:
Pripremite sve što je potrebno i položite na površinu:
Get together everything you need and lay them out::
Pripremite sve što Vam je potrebno i položite na površinu:
Getting off to a good start!
Važan je dobar početak
getting older
tarenje
Getting ready to inject
Priprema za injiciranje
GETTING READY TO INJECT THE PREPARED MEDICINE
PRIPREMA ZA UBRIZGAVANJE PRIPREMLJENOG LIJEKA
GETTING STARTED
POČETAK UPORABE
Getting the dose or timing of injections wrong can lead to serious side effects.
Nepravilno doziranje ili dinamika primjene injekcija može prouzročiti ozbiljne nuspojave.
Getting the KwikPen ready to use (Please see user manual)
Priprema KwikPen brizgalice za uporabu (pogledajte Priručnik za uporabu)
Getting your GONAL-f pre-filled pen ready for injection
Priprema napunjene brizgalice lijeka GONAL-f za injekciju
Getting your prefilled pen ready for injection
Priprema napunjene brizgalice za injekciju
GGT increase (c)
povišenje GGT (c)
GGT increased Weight increased
Povišeni GGT Povećanje tjelesne težine
GGT), weight increasede, heart rate increasede, CPK
eriteme, hiperhidrozae, generalizirani svrbeže, iritacija kožee, kontaktni dermatitise, generalizirani osipe
GH <2.5 μg/l
GH <2,5 μg/l
GH <2.5 μg/l and IGF-1 ≤ULN
GH <2,5 μg/l i IGF-1 ≤GGN
GH <2.5 μg/l and normalised IGF-1*
GH <2,5 μg/l i normalizirani IGF-1
GH<2.5 μg/l
GH<2,5 μg/l
GH<2.5 μg/l and normalised IGF-1*
GH<2,5 μg/l i normalizirani IGF-1
GHB had no effect on mating, general fertility or sperm parameters and did not produce embryo- foetal toxicity in rats exposed to up 1000 mg/kg/day GHB (1.64 times the human exposure calculated in nonpregnant animals).
GHB nije imao učinka na parenje, opću plodnost ili parametre sjemena i nije uzrokovao embriofetalnu toksičnost u štakora izloženih dozama do 1000 mg/kg/dan GHB-a (1,64 puta veća izloženost nego u ljudi, izračunato u odnosu na životinje koje nisu gravidne).
GI bleeding
Gastrointestinalno krvaranje
GI haemorrhage,
krvarenje u probavnom sustavu,
GI motility agent
Lijekovi za gastrointestinalnu pokretljivost
GI motility agent Cisapride Increased plasma concentrations of cisapride.
Cisaprid Povišena koncentracija cisaprida u plazmi.
GI motility agent Cisapride Increased plasma concentrations of cisapride.
GI propulzivi Cisaprid Povećane koncentracije cisaprida u plazmi.
GI perforation (1)
gastrointestinalna perforacija (1)
GI perforation or fistula
GI perforacija ili fistula
GI perforations were reported in 0.9% of cabozantinib-treated RCC patients (3/331).
GI perforacije zabilježene su u 0,9 % bolesnika s RCC-om liječenih kabozantinibom(3/331).
GI tract symptoms including nausea, vomiting, anorexia and abdominal pain have been associated with cysteamine.
GI simptomi koji su povezani s cisteaminom uključuju mučninu, povraćanje, anoreksiju i bol u trbuhu.
GI ulceration and bleeding have been reported in patients receiving immediate-release cysteamine bitartrate.
Kod bolesnika koji primaju cisteamin bitartrat s trenutačnim oslobađanjem prijavljeni su GI ulceracije i krvarenje.
Giant cell tumours of bone are characterized by neoplastic stromal cells expressing RANK ligand and osteoclast-like giant cells expressing RANK.
Gigantocelularne tumore kosti karakteriziraju neoplastične stromalne stanice koje eksprimiraju RANK ligand i gigantske stanice nalik osteoklastima koje eksprimiraju RANK.
Giddiness
Omaglica.
Giddiness, vestibular syndrome
Omaglica, vestibularni sindrom
Gilbert’s disease) may exhibit increased serum concentrations of bilirubin and must be treated with caution.
Gilbertova bolest) može doći do povećane koncentracije bilirubina u serumu, pa je potreban oprez pri liječenju.
Gilead Sciences Ireland UC
Gilead Sciences Ireland UC.
Gilead Sciences Slovakia s.r.o.
Gilead Sciences Slovakia, s.r.o.
GILENYA 0.5 mg hard capsules
GILENYA 0,5 mg tvrde kapsule
GILENYA 0.5 mg hard capsules Fingolimod
GILENYA 0,5 mg tvrde kapsule fingolimod
Gilenya 0.5 mg hard capsules have a white opaque body and bright yellow opaque cap.
Gilenya 0,5 mg tvrde kapsule imaju bijelo neprozirno tijelo i svijetložutu neprozirnu kapicu.
Gilenya at two doses (0.5 mg and 1.25 mg) has been investigated in three main studies in MS patients.
Lijek Gilenya u dvije doze (0,5 mg i 1,25 mg) ispitan je u tri glavna ispitivanja među osobama oboljelima od multiple skleroze.
Gilenya can be taken with or without food.
Gilenyu možete uzimati s hranom ili bez nje.
Gilenya has not been studied in multiple sclerosis patients with concomitant diabetes mellitus.
Gilenya nije bila ispitivana u bolesnika s multiplom sklerozom koji su istodobno imali i dijabetes mellitus.
Gilenya is a medicine that contains the active substance fingolimod.
Gilenya je lijek koji sadrži djelatnu tvar fingolimod.
Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults with highly active multiple sclerosis (MS).
Gilenya se ubraja u vrstu lijekova koji modificiraju tijek bolesti, a primjenjuje se u liječenju odraslih osoba s visoko aktivnom multiplom sklerozom.
Gilenya is also not recommended in patients with certain cardiovascular disease or a history of cardiovascular or cerebrovascular disease (problems with the blood supply to the brain).
Lijek Gilenya također se ne preporučuje bolesnicima s određenim kardiovaskularnim bolestima ili poviješću kardiovaskularnih i cerebrovaskularnih bolesti (problemima s opskrbom mozga krvlju).
Gilenya is available in packs containing 7, 28 or 98 capsules or in multipacks containing 84 capsules (3 packs of 28 capsules).
Gilenya je dostupna u pakiranjima koja sadrže 7, 28 ili 98 kapsula ili u višestrukim pakiranjima koja sadrže 84 kapsula (3 pakiranja od 28 kapsula).
Gilenya is indicated as single disease modifying therapy in highly active relapsing remitting multiple sclerosis for the following adult patient groups:
Gilenya je indicirana kao monoterapija koja modificira tijek bolesti u visoko aktivne relapsno- remitirajuće multiple skleroze u sljedećim skupinama odraslih bolesnika:
Gilenya is known to cause lowering of the heart rate at the beginning of treatment.
Poznato je da lijek Gilenya uzrokuje snižavanje srčane frekvencije na početku terapije.
Gilenya is not intended to be used in children and adolescents below 18 years old as it has not been studied in MS patients below 18 years old.
Gilenya nije namijenjena za upotrebu u djece i adolescenata mlađih od 18 godina, budući da nije bila ispitivana u bolesnika oboljelih od MS-a mlađih od 18 godina.
GILENYA is not recommended in patients concomitantly taking Class Ia or Class III anti- arrhythmic medicines.
GILENYA se ne preporučuje u bolesnika koji istodobno uzimaju antiaritmike skupine Ia ili skupine III.
GILENYA is not recommended in patients concomitantly taking medicines which are known to decrease the heart rate.
GILENYA se ne preporučuje u bolesnika koji istodobno uzimaju lijekove za koje se zna da snižavaju srčanu frekvenciju.
GILENYA is not recommended in patients with cardiac disease or those taking medicines concomitantly known to decrease heart rate and they should tell any doctor they see that they are being treated with GILENYA.
GILENYA se ne preporučuje u bolesnika s bolešću srca ili u onih koji istodobno uzimaju lijekove za koje je poznato da snižavaju srčanu frekvenciju te bi oni trebali obavijestiti svakog liječnika kojeg posjete da se liječe GILENYOM.
Gilenya is used in the type of MS known as ‘relapsing- remitting’, when the patient has attacks (relapses) in between periods with decreased symptoms (remissions).
Gilenya se koristi kod relapsno-remitirajućeg oblika multiple skleroze, pri čemu bolesnik ima napadaje (relapse) između razdoblja smanjenih simptoma (remisije).
GILENYA may increase the risk of infections.
GILENYA može povećati rizik od infekcija.
Gilenya must not be used in patients at risk of infections due to a weakened immune system, patients with a severe active infection or a long-term active infection such as hepatitis, cancer or severe liver problems.
Lijek Gilenya ne smiju koristiti bolesnici s rizikom od infekcija zbog oslabljenog imunosnog sustava, bolesnici s teškom aktivnom infekcijom ili dugotrajnom aktivnom infekcijom poput hepatitisa, bolesnici koji boluju od raka ili imaju ozbiljne probleme s jetrom.
GILENYA reduces peripheral blood lymphocyte counts.
GILENYA smanjuje broj limfocita u perifernoj krvi.
Gilenya should be used with caution in these patients due to a potential increase in the risk of macular oedema (see sections 4.4 and 4.8).
Gilenyu treba primjenjivati s oprezom u tih bolesnika zbog potencijalnog povećanja rizika od makularnog edema (vidjeti dijelove 4.4 i 4.8).
Gilenya was shown to be more effective than placebo and beta-interferon in reducing the number of relapses.
Dokazano je da je lijek Gilenya učinkovitiji od placeba i interferona beta u smanjivanju broja relapsa.
Gilts and sows: Administer one 2 ml dose by deep intramuscular injection in accordance with the following vaccination scheme:
Nazimice i krmače: Jednu dozu 2 ml cjepiva injicirajte duboko intramuskularno u skladu sa slijedećim rasporedom cijepljenja:
Gilts: One injection, followed 3 to 4 weeks later by a second injection, at least 2 weeks before mating.
Nazimice: Jedna injekcija, nakon koje slijedi za 3 do 4 tjedna druga injekcija, najmanje 2 tjedna prije parenja.
Gilts: One injection, followed 3 to 4 weeks later by a second injection, at least 2 weeks before mating.
Nazimice: Jedna injekcija, nakon koje slijedi za 3 do 4 tjedna, druga injekcija, najmanje 2 tjedna prije parenja.
Gimeracil inhibits the metabolism of 5-FU by reversibly and selectively inhibiting DPD, the primary metabolic enzyme for 5-FU, so that higher plasma concentrations of 5-FU are achieved with the administration of a lower dose of tegafur.
Gimeracil inhibira metabolizam 5-FU-a reverzibilnom i selektivnom inhibicijom DPD-a, primarnog metaboličkog enzima 5-FU-a, čime se postiže viša koncentracija 5-FU-a u plazmi primjenom niže doze tegafura.
Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipationA, diarrhoea, vomitingA
Krvarenje iz desni, krvarenje u gastrointestinalnom traktu (uključujući rektalno krvarenje) bolovi u gastrointestinalnom traktu i abdomenu, dispepsija, mučnina, konstipacijaA, proljev, povraćanjeA
Gingival bleeding, gastrointestinal tract haemorrhage (incl. rectal haemorrhage), gastrointestinal and abdominal pains, dyspepsia, nausea, constipationA, diarrhoea, vomitingA
Krvarenje iz desni, krvarenje u gastrointestinalnom traktu (uključujući rektalno krvarenje), gastrointestinalni i abdominalni bolovi, dispepsija, mučnina, konstipacijaA, proljev, povraćanjeA
Gingival disorders
Poremećaji desni
Gingival hyperplasia (≥ 1/100 to < 1/10), colitis including cytomegalovirus colitis, (≥ 1/100 to < 1/10), pancreatitis, (≥ 1/100 to < 1/10) and intestinal villous atrophy.
Hiperplazija gingive (≥ 1/100 do < 1/10), kolitis, uključujući citomegalovirusni kolitis (≥ 1/100 do < 1/10), pankreatitis (≥ 1/100 do < 1/10) i atrofija crijevnih resica.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegalovirus colitis (≥1/100 to <1/10), pancreatitis (≥1/100 to <1/10) and intestinal villous atrophy.
Hiperplazija gingive (≥1/100 do <1/10), kolitis, uključujući citomegalovirusni kolitis (često), pankreatitis (često) i atrofija crijevnih resica.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegalovirus colitis, (≥1/100 to <1/10), pancreatitis (≥1/100 to <1/10) and intestinal villous atrophy.
Hiperplazija gingive (≥1/100 i <1/10), kolitis, uključujući citomegalovirusni kolitis (≥1/100 i <1/10), pankreatitis (≥1/100 i <1/10) i atrofija crijevnih resica.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegalovirus colitis, (≥1/100 to <1/10), pancreatitis, (≥1/100 to <1/10) and intestinal villous atrophy.
Hiperplazija gingive (≥1/100 i <1/10), kolitis, uključujući citomegalovirusni kolitis (≥1/100 i <1/10), pankreatitis (≥1/100 i <1/10) i atrofija crijevnih resica.
Gingival hyperplasia (≥1/100 to <1/10), colitis including cytomegaloviruscolitis, (≥1/100 to <1/10), pancreatitis (≥1/100 to <1/10) and intestinal villous atrophy.
Hiperplazija gingive (≥1/100 i <1/10), kolitis, uključujući citomegalovirusni kolitis (≥1/100 i <1/10), pankreatitis (≥1/100 i <1/10) i atrofija crijevnih resica.
gingival hypertrophy, dyspepsia, dry mouth
povraćanje, hipertrofija desni, dispepsija, suhoća usta
Gingival infection
infekcije gingive
Gingivitis
0 (0,0)
gingivitis, constipation, loose stools
glositis, gingivitis, konstipacija, mekana stolica
Ginkgo biloba extracts (herbal preparation)
ekstrakti Ginkga bilobe (biljni pripravak).
Ginkgo biloba extracts (herbal preparation).
Ekstrakt Ginko biloba (biljni pripravak).
GIOTRIF 20 mg film-coated tablets are white to yellowish and round shaped.
GIOTRIF 20 mg filmom obložene tablete su bijele do žućkaste boje i okruglog oblika.
GIOTRIF 20 mg film-coated tablets Hypromellose (E464)
GIOTRIF 20 mg filmom obložene tablete hipromeloza (E464)
GIOTRIF 20 mg tablets afatinib
GIOTRIF 20 mg tablete afatinib
GIOTRIF 30 mg film-coated tablets are dark blue and round shaped.
GIOTRIF 30 mg filmom obložene tablete su tamnoplave boje i okruglog oblika.
GIOTRIF 30 mg tablets afatinib
GIOTRIF 30 mg tablete afatinib
GIOTRIF 30, 40 and 50 mg film-coated tablets Hypromellose (E464)
GIOTRIF 30, 40 i 50 mg filmom obložene tablete hipromeloza (E464)
GIOTRIF 40 mg film-coated tablets are light blue and round shaped.
GIOTRIF 40 mg filmom obložene tablete su svijetloplave boje i okruglog oblika.
GIOTRIF 40 mg film-coated tablets EU/1/13/879/007
GIOTRIF 40 mg filmom obložene tablete
GIOTRIF 40 mg tablets afatinib
GIOTRIF 40 mg tablete afatinib
GIOTRIF 50 mg film-coated tablets are dark blue and oval shaped.
GIOTRIF 50 mg filmom obložene tablete su tamnoplave boje i ovalnog oblika.
GIOTRIF 50 mg tablets afatinib
GIOTRIF 50 mg tablete afatinib
GIOTRIF film-coated tablets are available in packs containing 1, 2 or 4 perforated unit dose blisters.
GIOTRIF filmom obložene tablete su dostupne u pakiranjima koja sadrže 1, 2 ili 4 perforirana blistera djeljiva na jedinične doze.
GIOTRIF has not been studied in patients with eGFR <15 mL/min/1.73m² or on dialysis.
GIOTRIF nije ispitan u bolesnika s eGFR<15 ml/min/1,73 m2 ili na dijalizi.
Girl or woman of childbearing age:
Djevojke ili žene u reproduktivnoj dobi:
Girls with growth failure associated with Turner syndrome (n=108)
Djevojke sa zastojem rasta povezanim s Turnerovim sindromom (n=108)
Girona Spain
Girona Španjolska
Girona Spain
Španjolska
Give HEMANGIOL directly into your child's mouth using the oral syringe supplied with the bottle.
Dajte HEMANGIOL izravno u djetetova usta pomoću oralne štrcaljke isporučene uz bocu.
Give HEMANGIOL to your child
Dajte HEMANGIOL djetetu
Give injection
Dajte si injekciju
Give Kalydeco to your child for as long as your child’s doctor recommends.
Nastavite davati Kalydeco svom djetetu onoliko dugo koliko to preporučuje djetetov liječnik.
Give orally.
Dajte peroralno.
Give Procox into the dog's mouth.
Aplicirajte Procox psu u usta
Give Procox into the mouth of the dog.
Aplicirajte suspenziju psu u usta.
Give the 1st dose to the child no later than 3 weeks before you leave for your trip.
Dajte djetetu 1. dozu ne kasnije od 3 tjedana prije odlaska na putovanje.
Give the 2nd dose to the child at least 1 week after the 1st dose.
Dajte djetetu 2. dozu najmanje 1 tjedan nakon 1. doze.
Give the 3rd dose at least one week after the 2nd dose and at least one week before your trip.
Dajte 3. dozu najmanje 1 tjedan nakon 2. doze i najmanje 1 tjedan prije vašeg putovanja.
Give the entire contents of the bottle to the patient using the accompanying oral syringe.
Dajte cijeli sadržaj boce bolesniku pomoću priložene štrcaljke za usta.
Give the first dose of parenteral anticoagulant at the time the next Xarelto dose would be taken.
Prva doza parenteralnog antikoagulansa mora se dati u vrijeme kada bi se uzela sljedeća doza lijeka Xarelto.
Give the full dose with a new pen.
ili primijeniti cijelu dozu iz nove brizgalice.
Give the medicine into the mouth
Primijenite lijek u usta
Give the medicine to the child.
Dajte lijek djetetu.
Give the medicine to the patient
Dajte lijek bolesniku
Give the mixture of food and capsule contents to the child, making sure he or she eats the full amount (illustration f).
Dajte djetetu mješavinu hrane i sadržaja kapsule, pazeći da ono pojede svu količinu (ilustracija f).
give the next dose return the bottle to the pharmacist or doctor as soon as possible for a fresh supply.
dati sljedeću dozu vratiti bocu ljekarniku ili liječniku što je prije moguće radi novog izdavanja.
Give the partial dose and then give the remaining dose using a new pen. or
primijeniti taj dio, a preostali dio primijeniti iz nove brizgalice,
Give the patient the full dose within 2 hours of opening the sachet.
Dajte bolesniku cijelu dozu unutar 2 sata od otvaranja vrećice.
Give the vaccine straight away.
Odmah primijenite cjepivo.
Give the vaccine straight away.
Položaj djeteta kod primjene cjepiva
give you other medicines in order to prevent complications and reduce your symptoms, withhold the next dose of Nivolumab BMS, or stop your treatment with Nivolumab BMS altogether.
dati druge lijekove kako bi spriječio komplikacije i ublažio simptome odgoditi primjenu sljedeće doze lijeka Nivolumab BMS ili posve obustaviti liječenje lijekom Nivolumab BMS
give you other medicines in order to prevent complications and reduce your symptoms, withhold the next dose of OPDIVO, or stop your treatment with OPDIVO altogether.
dati druge lijekove kako bi spriječio komplikacije i ublažio simptome odgoditi primjenu sljedeće doze lijeka OPDIVO ili posve obustaviti liječenje lijekom OPDIVO
give your child cold water to drink seek urgent medical assistance.
dajte djetetu hladnu vodu za piće potražite hitnu medicinsku pomoć.
give your child plenty of cold water to drink
mora piti mnogo hladne vode
Give yourself the injection at the same time each day.
Injekciju si dajte svakog dana u isto vrijeme.
Given as monotherapy, the recommended starting dose for capecitabine in the adjuvant treatment of colon cancer, in the treatment of metastatic colorectal cancer or of locally advanced or metastatic breast cancer is 1250 mg/m2 administered twice daily (morning and evening; equivalent to 2500 mg/m2 total daily dose) for 14 days followed by a 7-day rest period.
Preporučena početna doza kapecitabina primijenjenog kao monoterapija u adjuvantnom liječenju karcinoma debelog crijeva, liječenju metastatskog kolorektalnog karcinoma ili u liječenju lokalno uznapredovalog ili metastatskog karcinoma dojke iznosi 1250 mg/m² i uzima se dvaput dnevno (ujutro i navečer, što odgovara ukupnoj dnevnoj dozi od 2500 mg/m²) tijekom 14 dana, nakon čega slijedi 7 dana pauze.
Given eluxadoline’s action at opioid receptors, administration of a narcotic mu opioid antagonist, such as naloxone, should be considered.
S obzirom na to da eluksadolin djeluje na opioidne receptore, treba uzeti u obzir primjenu narkotičkog antagonista mi- opioidnih receptora, kao što je nalokson.
Given eluxadoline’s local action in the GI tract, low Foral and lack of metabolism, prospective clinical studies regarding differences in age, body mass index (BMI), ethnicity, and gender were deemed unnecessary.
S obzirom na lokalno djelovanje eluksadolina u GI traktu, niski Foral i nedostatak metabolizma, smatralo se da su nepotrebna prospektivna klinička ispitivanja u vezi razlika u dobi, indeksu tjelesne mase (ITM), etničkog podrijetla i spola.
given in integrase inhibitor-
inhibitor integraze.
Given its genotoxic potential, 6–mercaptopurine is potentially carcinogenic.
S obzirom na svoj genotoksični potencijal 6-merkaptopurin je potencijalno kancerogen.
Given its low in vitro plasma protein binding ( 1%), decitabine is unlikely to displace co-administered medicinal products from their plasma protein binding.
S obzirom na nisko vezanje na proteine plazme ( 1%) in vitro, nije vjerojatno da će decitabin istisnuti istodobno primjenjivane lijekove s njihovih mjesta vezanja na proteine plazme.
Given its toxic nature, special precautions should be taken in handling DepoCyte.
Zbog toksičnosti potrebne su posebne mjere opreza pri rukovanju DepoCyteom.
given over 2-5 days
tijekom 2-5 dana
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that Sildenafil Actavis will alter the clearance of substrates of these isoenzymes.
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 M, nije vjerojatno da će Sildenafil Actavis promijeniti klirens supstrata tih izoenzima.
Given sildenafil peak plasma concentrations of approximately 1 µM after recommended doses, it is unlikely that sildenafil will alter the clearance of substrates of these isoenzymes.
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 M, nije vjerojatno da će sildenafil promijeniti klirens supstrata tih izoenzima.
Given sildenafil peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that Sildenafil Teva will alter the clearance of substrates of these isoenzymes.
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 M, nije vjerojatno da će Sildenafil Teva promijeniti klirens supstrata tih izoenzima.
Given sildenafil peak plasma concentrations of approximately 1 μM after recommended doses, it is unlikely that VIAGRA will alter the clearance of substrates of these isoenzymes.
S obzirom da su nakon preporučenih doza vršne koncentracije sildenafila u plazmi približno 1 M, nije vjerojatno da će VIAGRA promijeniti klirens supstrata tih izoenzima.